TCM Herbs For Osteoporosis: Can Cistanche And Wenshen Tongluo Zhitong Decoction Help?
Jan 06, 2026
Osteoporosis (OP) and osteoarthritis (OA) are two of the most common chronic skeletal conditions affecting aging populations worldwide. While modern medicine focuses on hormone therapy and calcium supplementation, a growing number of researchers and patients are turning to Traditional Chinese Medicine (TCM) for safer, holistic solutions. Among these, Cistanche and a classic Chinese formula called Wenshen Tongluo Zhitong Fang (WSTZF) have shown promising results in both basic and clinical research.
In this article, we explore a recent animal study on the effects of WSTZF in rats with coexisting OP and OA, while also drawing connections to Cistanche glycosides, another TCM ingredient already studied for bone health. This blog aims to answer the question: Can TCM herbs like Cistanche and WSTZF help treat osteoporosis?
Why Combine OP and OA in Research?
According to epidemiological data, approximately 95% of osteoporosis patients have at least one comorbidity, with more than 50% of postmenopausal women suffering from both osteoporosis and osteoarthritis. These conditions share overlapping mechanisms-chronic inflammation, hormonal imbalance, and bone-cartilage degeneration.
From a TCM perspective, both diseases fall under the categories of "Gu Bi" (bone impediment) and "Gu Wei" (bone flaccidity), often stemming from kidney deficiency, qi stagnation, blood stasis, and spleen weakness. That's why formulas that tonify the kidney and activate circulation are often used for both.
different Specs of cistanche extract
Study Overview: WSTZF and the HIFs/OPG/RANKL Pathway
In a recent preclinical study conducted by researchers in Jiangsu, China, 35 female SD rats were randomly divided into five groups:
Sham-operated (control)
Model (OP + OA)
Alendronate-treated group (standard anti-OP drug)
Low-dose WSTZF
High-dose WSTZF
The OP+OA model was induced through bilateral ovariectomy (to mimic postmenopausal osteoporosis) and a modified Hulth surgical procedure to simulate knee osteoarthritis.
Key Interventions:
WSTZF was administered at 14.76 and 29.52 g/kg·d via gavage for 10 weeks.
Alendronate was given weekly at 6.3 mg/kg as a positive control.
Biomarkers, cartilage structure, and bone density were evaluated post-treatment.
Results: Significant Improvements in Bone and Cartilage Health
Compared to the model group, the high-dose WSTZF group showed significant improvements in:
Bone density and trabecular structure (BV/TV increased, Tb.Sp decreased)
Cartilage morphology scores (Collins and Mankin scores decreased)
Inflammatory cytokines (TNF-α, IL-1β decreased)
Bone metabolism markers:
OPG/RANKL ratio increased, indicating reduced bone resorption
COL1A2, COL2A1 increased, indicating improved bone and cartilage matrix synthesis
MMP9, MMP13 decreased, indicating reduced degradation
Modulation of the HIF-1α and HIF-2α pathways, crucial in hypoxia-related bone-cartilage remodeling
These results suggest that WSTZF may regulate the HIFs/OPG/RANKL signaling axis, rebalancing bone metabolism and improving joint health.
What About Cistanche?
Another TCM herb gaining attention is Cistanche tubulosa, also known as "desert ginseng." A separate study has shown that glycosides of cistanche (GCs):
Promote osteoblast activity
Inhibit osteoclasts
Reduce oxidative stress
Modulate sex hormone levels
Engage the Wnt/β-catenin and OPG/RANKL/RANK pathways
Show good safety and tolerability in animal models
These mechanisms overlap significantly with those of WSTZF, suggesting synergistic potential in formulas or supplements containing both.
Why Are These Findings Important?
Most pharmaceutical treatments for osteoporosis come with side effects or long-term risks, especially in elderly patients with multiple conditions. TCM formulas like WSTZF and herbs like Cistanche offer a natural, multi-targeted approach that addresses both bone density loss and inflammatory joint degeneration.
The use of integrative therapies-combining conventional and herbal medicine-is becoming more accepted in aging and bone health management. As the population ages, safe and effective natural therapies will be in high demand.
Conclusion: A TCM-Based Future for Bone Health?
The findings from both the WSTZF study and Cistanche research suggest that Traditional Chinese Medicine can play a vital role in osteoporosis and osteoarthritis management. While more clinical trials are needed, the evidence from animal models is promising.
Whether you're a supplement formulator, health-conscious consumer, or practitioner of integrative medicine, Cistanche and WSTZF deserve your attention.
Keywords:
TCM Herb for Osteoporosis, Cistanche for Bone Health, Osteoarthritis Natural Treatment, WSTZF, HIFs/OPG/RANKL, Cistanche Glycosides, Bone Metabolism Herbs, Natural Bone Density Supplement, Chinese Medicine for Osteoporosis
References:
Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35:75–83.
Zhang Yili, Huang Xinyi, Qi Baoyu, et al. Significance and Research Outlook of Comorbidities in the Elderly. Chinese Journal of Evidence-Based Medicine. 2023;23(7):862-868.
Research Progress of Total Glycosides of Cistanche in the Treatment of Osteoporosis. https://www.xjcistanche.com/news/cistanche-in-the-treatment-of-osteoporosis-85229223.html
Zheng Suyang et al. Clinical Observation and Prescription Optimization of WSTZF in Primary Osteoporosis. Liaoning Journal of Traditional Chinese Medicine. 2016;43(10):2098-2100.
Tan JK, et al. Impacts of hypoxia on osteoclast formation and activity. Int J Mol Sci. 2021;22(18):10146.
Knowles HJ. Distinct roles for HIF-1α and HIF-2α in osteoclast function. Sci Rep. 2020;10:21072.
If you're looking to source high-quality Cistanche extract for supplement production, check out the trusted supplier: Chengdu Wecistanche Bio-Tech Co., Ltd (https://www.xjcistanche.com)
For republishing or partnership, contact: admin@wecistanche.com
